|
 MedGenome, a leading global genomics-driven diagnostics and research services company, announced the appointment of Dr Amit Kakar as chairman of its board, effective immediately.
Dr Kakar takes over from Dr Felix Olale, MD, PhD, who concluded his two year term as chairman of the Board and will focus his efforts on leading the growth of MedGenome’s US and North America business.
Dr Amit has served on the MedGenome board of directors since 2022 and is managing partner and head of Asia at Novo Holdings, a global life sciences investor wholly owned by the Novo Nordisk Foundation, an independent philanthropic enterprise foundation. He has over 30 years of experience in the healthcare and life sciences industry and serves on the boards of Doctor Anywhere, an omni-channel healthcare service provider; ESCO, a Singapore-based life science company; and Qure.ai, a leading health tech firm headquartered in India.
“MedGenome has been at the forefront of revolutionizing healthcare through its deep technology and innovation capabilities in the field of genomics. I look forward to working closely with the board and management team as we continue to play our part in making healthcare solutions affordable and accessible for all. Together with the talented team at MedGenome, we will work towards expanding our reach and ensuring that our solutions can make a difference in the lives of people across the globe,” said Dr Kakar.
Dr Kakar previously served as the head of healthcare investments at Avenue Capital for 8 years where he was responsible for the company’s pan-Asia healthcare investments. He was also part of GE Healthcare for over 14 years, holding various senior positions in India, China, and the US; and was head of M&A and business development at Everlife Asia in Singapore.
Mahesh Pratapneni, group CEO & co-founder of MedGenome said, “We look forward to working closely with Dr Amit to ensure MedGenome continues to make a positive impact on human lives. I also want to thank Dr Felix for his tremendous contributions as chair and look forward to his continued contribution as a valued member of the MedGenome leadership team.”
This appointment reiterates MedGenome’s commitment to strong governance and its dedication to the mission of improving global health by providing data driven insights into complex diseases through its genomic research and diagnostics solutions.
|